SEC Company Response from CNS Pharmaceuticals, Inc. (CNSP) (CIK 0001729427) (CNSP) — Nov 5, 2019
CNS Pharmaceuticals, Inc. (CNSP) (CIK 0001729427)
Date: Nov. 5, 2019 · CIK: 0001729427 · Accession: 0001683168-19-003436
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232443
Letter
Re: CNS Pharmaceuticals, Inc.
November 5,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1
Registration No. 333-232443
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on November 7, 2019, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
November 5,
2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
Registration No. 333-232443
Ladies and Gentlemen:
Pursuant to Rule 461
of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby
respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be
declared effective at 4:30 P.M. (Eastern Time) on November 7, 2019, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
By: /s/ John Climaco
Name: John Climaco
Title: Chief Executive Officer